Reinforcement tumor immunotherapy using RNF43 peptide pulse dendritic cells and activated CTL clone for advanced solid tumor patient

Terumasa Hisano, Kashiya Takasugi, Mutsunori Iga, Ryo Kurita, Yasuji Yoshikawa, Kensaburo Tani

Research output: Contribution to journalArticle

Abstract

There are few reports that conventional tumor immunotherapy shows a stable curative effect. The disappearance in the short term of the activated cytotoxic T-lymphocyte (CTL) clone administered to the patient and the inactivation of activated CTL in the cancerous part by regulatory T cells etc. are suggested to be the main causes. To overcome these problems, we planned a new clinical strategy to target the RNF43 peptide expressed abundantly in colon cancer, as the tumor-specific antigen. Based on our in vitro study results, we planned the following Phase I clinical protocol. First, we generate the activated CTL population which can react to the RNF43 peptide in vitro. Then, we use cyclophosphamide for the exclusion of regulatory T cells and administer RNF43 peptide pulse dendritic cells (DC) and interleukin-2 (IL-2) for maintenance and further activation of the activated CTL clone in vivo when we administer it.

Original languageEnglish
Pages (from-to)332-337
Number of pages6
JournalBiotherapy
Volume22
Issue number5
Publication statusPublished - Sep 2008

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Reinforcement tumor immunotherapy using RNF43 peptide pulse dendritic cells and activated CTL clone for advanced solid tumor patient'. Together they form a unique fingerprint.

  • Cite this

    Hisano, T., Takasugi, K., Iga, M., Kurita, R., Yoshikawa, Y., & Tani, K. (2008). Reinforcement tumor immunotherapy using RNF43 peptide pulse dendritic cells and activated CTL clone for advanced solid tumor patient. Biotherapy, 22(5), 332-337.